Avicenna Oncology GmbH

Avicenna Oncology GmbH

Avicenna Oncology GmbH, is dedicated to the discovery and early development of new generation of toxic payloads and ImmunoPayloads (ImPs) for the development of Antibody-Drug Conjugates (ADC) against cancer.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttp://www.avicenna-oncology.com
Disease Focus
STOCK CODENon Listed
Address
Hochbergerstrasse 60 CCH-4057
Basel
Switzerland
Email
Contact Number
+41 0 61 63 330 74

Avicenna Oncology GmbH, is dedicated to the discovery and early development of new generation of toxic payloads and ImmunoPayloads (ImPs) for the development of Antibody-Drug Conjugates (ADC) against cancer.

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/avicenna-oncology” connections=”true” suffix=””]

Avicennas proprietary AviSenseë Platform is used for the scouting, evaluation and development of its innovative assets and is currently developing new generation of payloads with differentiated mechanism of actions: Toxic Payloads and ImmunoPayloads (ImPs). ImPs are a new class of therapeutics that have the ability to activate a highly potent and specific T cell response to recognize and destroy tumoral cells. ImPs are unique constructs designed against oncogenic targets and fused with virus-derived immuno-dominant epitopes.

In Aug 2017, Avicenna signs a research deal with Cellectar Biosciences (Nasdaq:CLRB), for the development of new phospholipid drug conjugates (PDCs). Under the terms, Avicenna will provide their novel payloads to Cellectar, which will leverage its expertise in chemical conjugation to link the molecules to its phospholipid ether (PDC platform). Cellectar will oversee the in vitro and in vivo testing of these molecules alongside an antibody drug conjugate with the same payload. Both companies will have the option to advance the development of any of the newly conjugated molecules (PDCs). Financial terms remains undisclosed.

Avicenna Oncology activities are financed by private investors and is located at newly established BASEL INKUBATOR Startup Center, Basel.